New clinical advances in immunotherapy for the treatment of solid tumours

Immunology

Volumn 145, Issue 2, 2015, Pages 182-201

  Zavala, Valentina A ^a   Kalergis, Alexis M ^a,b,c  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c INSERM   (France)

Author keywords

Cancer; Clinical; Immunotherapy; Programmed cell death 1; T lymphocyte associated antigen 4; Trial

Indexed keywords

ALPHA FETOPROTEIN; CANCER TESTIS ANTIGEN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; DACARBAZINE; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IPILIMUMAB; MELANOMA ANTIGEN; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; NIVOLUMAB; ONCOFETAL ANTIGEN; PEMBROLIZUMAB; PEPTIDE VACCINE; PERTUZUMAB; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; TALIMOGENE LAHERPAREPVEC; TECEMOTIDE; TG 4010; TRASTUZUMAB; TUMOR ANTIGEN; VELIMOGENE ALIPLASMID; VEMURAFENIB; CANCER ANTIBODY; MONOCLONAL ANTIBODY;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL TOLERANCE; KIDNEY CARCINOMA; MELANOMA; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; SOLID TUMOR; ANIMAL; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84929658607     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12459     Document Type: Article

References (131)

1. DeVita VT, Rosenberg SA. Two hundred years of cancer research. N Engl J Med 2012; 366:2207-14.
2. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21:309-22.
3. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006; 1:119-50.
4. Evans A, Costello E. The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Front Physiol 2012; 3:270.
5. Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, Lardon F, Vermorken JB. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol 2010; 11:19.
6. DeNardo DG, Brennan DJ, Rexhepaj E et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1:54-67.
7. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci USA 2012; 109:2796-801.
8. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini P-L. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 2011; 60:319-26.
9. Mohammed ZM, Going JJ, Edwards J, Elsberger B, Doughty JC, McMillan DC. The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 2012; 107:864-73.
10. Ascierto PA, Capone M, Urba WJ et al. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med 2013; 11:54.
11. NCI dictionary of cancer terms - National Cancer Institute [Internet] [WWW document]. URL http://www.cancer.gov/dictionary?cdrid=45729 [accessed on 7 September 2014].
12. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol 2014; 192:5451-8.
13. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23.
14. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011; 17:3520-6.
15. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22.
16. Robert C, Ribas A, Wolchok JD et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384:1109-17.
17. Monjazeb AM, Hsiao H-H, Sckisel GD, Murphy WJ. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. J Immunotoxicol 2012; 9:248-58.
18. Iezzi M, Quaglino E, Amici A, Lollini P-L, Forni G, Cavallo F. DNA vaccination against oncoantigens: a promise. Oncoimmunology 2012; 1:316-25.
19. Mann JR, Lakin GE, Leonard JC et al. Clinical applications of serum carcinoembryonic antigen and alpha-fetoprotein levels in children with solid tumours. Arch Dis Child 1978; 53:366-74.
20. Qian X, Li C, Pang B, Xue M, Wang J, Zhou J. Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker. PLoS ONE 2012; 7:e37225.
21. Ryu YJ, Kim CH, Kim HJ et al. Clinical significance of serial serum carcinoembryonic antigen values for treating rectal cancer with preoperative chemoradiotherapy. J Korean Soc Coloproctol 2012; 28:205-12.
22. Yang L, Chen X, Li Y, Yang J, Tang L. Declines in serum CYFRA21-1 and carcinoembryonic antigen as predictors of chemotherapy response and survival in patients with advanced non-small cell lung cancer. Exp Ther Med 2012; 4:243-8.
23. Aggarwal C, Meropol NJ, Punt CJ et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol 2013; 24:420-8.
24. Yang C, Ruffner MA, Kim S-H, Robbins PD. Plasma-derived MHC class II+ exosomes from tumor-bearing mice suppress tumor antigen-specific immune responses. Eur J Immunol 2012; 42:1778-84.
25. Ciravolo V, Huber V, Ghedini GC et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol 2012; 227:658-67.
26. Aung T, Chapuy B, Vogel D et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci U S A 2011; 108:15336-41.
27. Marleau AM, Chen C-S, Joyce JA, Tullis RH. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med 2012; 10:134.
28. Gnjatic S, Nishikawa H, Jungbluth AA et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006; 95:1-30.
29. Noguchi T, Kato T, Wang L et al. Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Cancer Res 2012; 72:1672-82.
30. Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37.
31. Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18:1254-61.
32. Bossi G, Buisson S, Oates J, Jakobsen BK, Hassan NJ. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol Immunother 2014; 63:437-48.
33. Singh-Jasuja H, Emmerich NPN, Rammensee H-G. The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother 2004; 53:187-95.
34. Hassan NJ, Adams K, Bossi G et al. Abstract 3525: IMCgp100: a novel bi-specific biologic for the treatment of malignant melanoma. Cancer Res 2012; 72(8 Suppl.):3525.
35. Salem ML, Rubinstein MP. Cole DJ. Tumours: Immunotherapy. 2007;. doi:10.1002/9780470015902.a0001432.pub2.
36. Bensinger WI. Allogeneic transplantation: peripheral blood vs. bone marrow. Curr Opin Oncol 2012; 24:191-6.
37. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54.
38. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236:219-42.
39. Brahmer JR, Tykodi SS, Chow LQM et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65.
40. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21:137-48.
41. Powles T, Eder JP, Fine GD et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515:558-62.
42. Herbst RS, Soria J-C, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-7.
43. Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM, Soefje SA. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract 2014; doi: 10.1177/1078155214538087.
44. + T cell dysfunction in melanoma patients. J Exp Med 2010; 207:2175-86.
45. + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010; 107:7875-80.
46. + T cells in metastases from melanoma patients. J Clin Invest 2011; 121:2350-60.
47. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207:2187-94.
48. + T lymphocytes. Eur J Immunol 1994; 24:3216-21.
49. + T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007; 117:3383-92.
50. Woo S-R, Turnis ME, Goldberg MV et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res NIH Public Access 2012; 72:917-27.
51. Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev 2011; 25:2559-72.
52. Hobo W, Novobrantseva TI, Fredrix H et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother 2013; 62:285-97.
53. Yu Z, Qian J, Wu J, Gao J, Zhang M. Allogeneic mRNA-based electrotransfection of autologous dendritic cells and specific antitumor effects against osteosarcoma in rats. Med Oncol 2012; 29:3440-8.
54. Cancer treatment & survivorship facts & figures: 2014-2015 acspc-042801.pdf [Internet]. [WWW document]. URL http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042801.pdf [accessed on 2 January 2015].
55. Dillman RO, Barth NM, VanderMolen LA, Mahdavi K, McClure SE. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm 2012; 27:337-43.
56. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008; 6:751-9.
57. Bollag G, Hirth P, Tsai J et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467:596-9.
58. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26.
59. Audemard A, de Raucourt S, Miocque S et al. Melanoma-associated retinopathy treated with ipilimumab therapy. Dermatology 2013; 227:146-9.
60. Dilling P, Walczak J, Pikiel P, Kruszewski WJ. Multiple colon perforation as a fatal complication during treatment of metastatic melanoma with ipilimumab - case report. Pol Przegl Chir 2014; 86:94-6.
61. Du Rusquec P, Saint-Jean M, Brocard A, Peuvrel L, Khammari A, Quéreux G et al. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma. J Immunother 2014; 37:348-50.
62. Voskens CJ, Goldinger SM, Loquai C et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE 2013; 8:e53745.
63. Akhtari M, Waller EK, Jaye DL, Lawson DH, Ibrahim R, Papadopoulos NE et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother 2009; 32:322-4.
64. Kaehler KC, Egberts F, Lorigan P, Hauschild A. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient. Melanoma Res 2009; 19:333-4.
65. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75.
66. Lipson EJ, Sharfman WH, Drake CG et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013; 19:462-8.
67. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33.
68. Topalian SL, Sznol M, McDermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30.
69. Press Announcements. FDA approves Keytruda for advanced melanoma. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm [accessed on 6 September 2014].
70. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44.
71. Ribas A, Hodi FS, Kefford R et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol 2014;32(5 Suppl.):LBA9000.
72. Hodi FS, Ribas A, Daud A et al. Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol 2014; 32(5 Suppl.):3006.
73. Doukas J, Rolland A. Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma. Cancer Gene Ther 2012; 19:811-7.
74. Bedikian AY, Richards J, Kharkevitch D, Atkins MB, Whitman E, Gonzalez R. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 2010; 20:218-26.
75. Liu BL, Robinson M, Han Z-Q et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003; 10:292-303.
76. Senzer NN, Kaufman HL, Amatruda T et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27:5763-71.
77. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010; 17:718-30.
78. Kaufman HL, Bines SD. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 2010; 6:941-9.
79. Met O, Eriksen J, Svane IM. Studies on mRNA electroporation of immature and mature dendritic cells: effects on their immunogenic potential. Mol Biotechnol 2008; 40:151-60.
80. Van Brussel I, Berneman ZN, Cools N. Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system. Mediators Inflamm 2012; 2012:690643.
81. Van Driessche A, Ponsaerts P, Van Bockstaele DR, Van Tendeloo VFI, Berneman ZN. Messenger RNA electroporation: an efficient tool in immunotherapy and stem cell research. Folia Histochem Cytobiol 2005; 43:213-6.
82. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328-32.
83. + T cells responses in stage III and IV melanoma patients. Clin Cancer Res 2012; 18:5460-70.
84. Oshita C, Takikawa M, Kume A et al. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep 2012; 28:1131-8.
85. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463-75.
86. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-37.
87. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-82.
88. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61:4744-9.
89. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69:9330-6.
90. Mortenson ED, Fu Y-X. Adaptive immune responses and HER2/neu positive breast cancer. Curr Pathobiol Rep 2013; 1:37-42.
91. Barok M, Isola J, Pályi-Krekk Z et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 2007; 6:2065-72.
92. Perez EA, Suman VJ, Davidson NE et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011; 29:4491-7.
93. Tagliabue E, Sfondrini L, Regondi V et al. Chemotherapy can enhance trastuzumab-mediated ADCC. Cancer Res 2012;72(24 Suppl.):P5-18 - 10-P5 - 18-10.
94. Baselga J, Cortés J, Kim S-B et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109-19.
95. Swain SM, Kim S-B, Cortés J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013; 14:461-71.
96. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367:1783-91.
97. Welslau M, Diéras V, Sohn J-H et al. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer 2014; 120:642-51.
98. Miller KD, Diéras V, Harbeck N et al. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol 2014; 32:1437-44.
99. Mittendorf EA, Clifton GT, Holmes JP et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2012; 118:2594-602.
100. Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol 2006; 13:1085-98.
101. Carmichael MG, Benavides LC, Holmes JP, Gates JD, Mittendorf EA, Ponniah S et al. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer 2010; 116:292-301.
102. Morin J, Traoré A, Dionne G et al. Magnetic resonance-guided percutaneous cryosurgery of breast carcinoma: technique and early clinical results. Can J Surg 2004; 47:347-51.
103. Manenti G, Perretta T, Gaspari E et al. Percutaneous local ablation of unifocal subclinical breast cancer: clinical experience and preliminary results of cryotherapy. Eur Radiol 2011; 21:2344-53.
104. Sabel MS, Nehs MA, Su G, Lowler KP, Ferrara JLM, Chang AE. Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat 2005; 90:97-104.
105. Sabel MS, Su G, Griffith KA, Chang AE. Rate of freeze alters the immunologic response after cryoablation of breast cancer. Ann Surg Oncol 2010; 17:1187-93.
106. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JWW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008; 44:1345-89.
107. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013; 19:5300-9.
108. Lynch TJ, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30:2046-54.
109. Reck M, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013; 24:75-83.
110. Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004; 82:249-93.
111. Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007; 13(15 Pt 2):s4652-4.
112. Quoix E, Ramlau R, Westeel V et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011; 12:1125-33.
113. Butts C, Socinski MA, Mitchell PL et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15:59-68.
114. McNeel D, Nguyen L, Willia E, Higano C, Paul L, Dissis M. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate 2001; 47:222-9.
115. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089-94.
116. Beer TM, Schellhammer PF, Corman JM et al. Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. Urology 2013; 82:410-5.
117. Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099-105.
118. Chow W-H, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010; 7:245-57.
119. Rausch S, Kruck S, Stenzl A, Bedke J. IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy. Future Oncol 2014; 10:937-48.
120. Thompson RH, Gillett MD, Cheville JC et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004; 101:17174-9.
121. Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006; 66:3381-5.
122. Choueiri TK, Fay AP, Gray KP et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 2014; 25:2178-84.
123. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007; 13:1757-61.
124. Kang MJ, Kim KM, Bae JS et al. Tumor-infiltrating PD1-positive lymphocytes and FoxP3-positive regulatory T cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma. Transl Oncol 2013; 6:282-9.
125. Motzer RJ, Rini BI, McDermott DF et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2014; doi: 10.1200/JCO.2014.59.0703.
126. Ulloa-Montoya F, Louahed J, Dizier B et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013; 31:2388-95.
127. Snyder A, Makarov V, Merghoub T et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371:2189-99.
128. Yadav M, Jhunjhunwala S, Phung QT et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014; 515:572-6.
129. Gubin MM, Zhang X, Schuster H et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515:577-81.
130. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412-20.
131. Fojo AT, Noonan A. Why RECIST works and why it should stay. Cancer Res 2012; 72:5151-7.